Australian clinicians can now use a new pre-filled syringe to administer Eylea for four retinal conditions at a subsidised rate via the Pharmaceutical Benefits Scheme (PBS).1
The new pre-filled syringe provides clinicians with a further option for treatment, requiring fewer steps to prepare for intravitreal injection than vial presentations.
“EYLEA is a proven treatment option for reducing preventable vision loss in eligible patients, demonstrated in both clinical studies and real-world clinical settings,” said Dr Eduardo Pimenta, Country Medical Director at Bayer Pharmaceuticals Australia and New Zealand. “We’re extremely pleased to further enhance our treatment offering through the introduction of the pre-filled syringe.”
The new pre-filled syringe provides clinicians with a further option for treatment, requiring fewer steps to prepare for intravitreal injection than vial presentations
From 1 October 2020, PBS listing for Eylea includes administration via vial or pre-filled syringe for all listed indications, including the treatment of a newly listed indication, for use in patients with subfoveal choroidal neovascularisation due to pathologic myopia.1
Pathologic myopia (PM) is a severe form of myopia, or short-sightedness, associated with an abnormal elongation of the eyeball and high myopia. Choroidal neovascularisation (CNV) is a vision-threatening complication of PM and is characterised by the growth of pathologic new blood vessels from the choriocapillaris through a break in the Bruch’s membrane into the space under the retinal pigment epithelium or retina.2
Results of the Phase 3 MYRROR study of Eylea in myopic CNV (mCNV) demonstrate that a limited number of injections with Eylea given in the first eight weeks of treatment achieved clinically meaningful visual improvements and anatomic benefits that were maintained and extended through week 48.3
The PBS listing of Eylea for subfoceal mCNV is expected to benefit around 700 Australian patients each year.4
“Bayer is committed to making Eylea accessible for all patients who may benefit. We set out to provide patients suffering from mCNV with greater access to an effective, sight-saving treatment, and we’re thrilled to have secured increased access via the PBS,” said Dr Eduardo Pimenta.
- Australian Government Department of Health. Pharmaceutical Benefits Schedule. Available at:
http://www.pbs.gov.au/pbs/home;jsessionid=iuycz8ls6usw1l3aszoquvpxz. Accessed October
- Neelam, K. et al. Choroidal neovascularization in pathological myopia. Progress in Retinal and
Eye Research. 2012;31(5):495-525. doi: 10.1016/j.preteyeres.2012.04.001
- Ikuno, K. et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal
Neovascularization: The MYRROR Study. Ophthalmology. 2015;122(6):1220-7. doi:
- Bayer. Data on file.